P1339: CLINICAL OUTCOMES OF PATIENTS WITH EBV+ PTLD FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION WHO FAIL RITUXIMAB: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY
J. Sanz-Caballer,
J. Storek,
G. Socié,
D. Thirumalai,
N. Guzman-Beccera,
P. Xun,
D. Kumar,
N. Sadetsky,
D. Dierickx,
J. Reitan,
A. Barlev,
M. Mohty
Affiliations
J. Sanz-Caballer
1 Servicio de Hematología, Hospital Universitari i politècnic La Fe, Valencia, Spain
J. Storek
2 Snyder Institute for Chronic Diseases, University of Calgary, Calgary, Canada
G. Socié
3 Service d’Hématologie-Greffe, Assistance Publique Hôpitaux de Paris-Hôpital Saint Louis, Paris, France
D. Thirumalai
4 Atara Biotherapeutics, Thousand Oaks, United States of America
N. Guzman-Beccera
4 Atara Biotherapeutics, Thousand Oaks, United States of America
P. Xun
4 Atara Biotherapeutics, Thousand Oaks, United States of America
D. Kumar
5 Ajmera Transplant Centre, University Health Network, Toronto, Canada
N. Sadetsky
6 Atara Biotherapeutics, South San Francisco, United States of America
D. Dierickx
7 Universitair Ziekenhuis Leuven, Leuven, Belgium
J. Reitan
8 RJM Group, LLC, Crown Point, United States of America
A. Barlev
6 Atara Biotherapeutics, South San Francisco, United States of America
